iZumi Bio Recruits iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
News Aug 07, 2008
iZumi Bio, Inc. has announced that John T. Dimos, Ph.D., first author of the landmark Science paper "Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons," will join its team of scientists translating induced pluripotent stem (iPS) cell research into patient benefits. Dimos' work demonstrates the potential for iPS-derived cells in regenerative medicine.
iPS cells are "reprogrammed" adult cells that have similar applications and potential to those of human embryonic stem (ES) cells, yet do not raise the same ethical concerns and can be generated in a patient-specific manner to maintain the disease-causing genetic profile while avoiding immune rejection.
Dimos' Science publication demonstrates that iPS cells derived from an individual patient can be differentiated into motor neurons, the cell type affected in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Large-scale, standardized production of such iPS-derived cells could be used for a variety of applications including models for drug discovery and cell-based therapies.
Dimos conducted his work as a postdoctoral fellow in Kevin Eggan's lab at the Harvard Stem Cell Institute. He earned his Ph.D. in Molecular Biology at Princeton University in Ihor Lemischka's laboratory, where he studied what defines a stem cell at the gene expression level.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE